Lindy graduated from Boston College’s Morrissey College of Arts and Sciences with a B.S. in Biochemistry. He is passionate about life sciences and biotechnology, specifically where innovation and market trends intersect to drive new solutions while also enriching the patient experience. Prior to graduation, Lindy held summer internships in the pharmaceutical and healthcare spaces and conducted biomechanics research for the Kenaley Lab in Boston College’s Biology Department. Before coming to Nuvera, Lindy worked as a laboratory technician in the material test lab at Teleflex.
Lindy is originally from eastern Pennsylvania. After playing competitive ice hockey for almost 20 years, he now enjoys golfing with his friends and riding his bike outdoors. He is an avid explorer, and looks forward to visiting new hiking mountains and trails in the Northeast and Midwest this summer. He is also a lover of games and puzzles, and rarely goes a day without completing the latest Wordle or Sudoku puzzle.
Motivation for Joining Nuvera
“I have a passion for improving the quality-of-care patients receive along their treatment journeys. During an internship at Shriners Children’s Hospital in Philadelphia, I witnessed first-hand the dedication and compassion it requires to not only help patients realize health milestones but also tackle the complexities of healthcare administration, education, access, and delivery. It takes a lot of creativity and personalized planning to craft the best patient experience, and this is how Nuvera approaches the work it does for its clients every day. I was excited by the opportunity to be on the strategic side of breaking down care barriers while also immersing myself in a culture of patient-centricity. I am thrilled to learn and grow alongside respected leaders in the healthcare space!”
Jump to a slide with the slide dots.
Overcome CGT capacity challenges with strategies for forecasting, staffing, and treatment center partnerships.
Read more
How CGT manufacturers can reduce treatment center burden through better workflows, training, logistics, and system integration.
Read more
How CGT manufacturers can reduce financial risk and reimbursement burden for treatment centers adopting commercial therapies.
Read more
Free drug removes price barriers, but Otarmeni shows why specialty therapy access still depends on PSPs, payers, and logistics.
Read more
As cell and gene therapies (CGTs) continue to enter the market, treatment centers have become the primary gatekeepers...
Read more